Crinetics price target raised to $74 from $70 at Citi

Citi analyst David Lebowitz raised the firm’s price target on Crinetics (CRNX) to $74 from $70 and keeps a Buy rating on the shares following the Q3 report. Crinetics is building a “powerful endocrinology portfolio and look forward to multiple, inflection-worthy catalysts in the coming year,” the analyst tells investors in a research note.